---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000018"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:19:40.201092+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences receives FDA IND clearance for CB-010 in lupus; GALLOP Ph1 trial expected by YE 2024

## Summary
- FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.
- Phase 1 GALLOP trial expected to initiate by year-end 2024; evaluates safety of single infusion with partial HLA matching.
- CB-010 clinical development expanded from oncology to autoimmune diseases; driven by encouraging initial ANTLER trial data in r/r B-NHL.
- Caribou reports $372.4M cash as of Dec 31, 2023, expected to fund operations into Q1 2026.
- Initial dose expansion data from ANTLER Phase 1 trial for 2L LBCL to be presented at a medical congress in Q2 2024.

## SEC filing metadata
- accession: 0001619856-24-000018
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000018/0001619856-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000018/crbu-20240404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000018
- JSON: https://secwatch.observer/filing/0001619856-24-000018.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.